YMTX insider filings
YUMANITY THERAPEUTICS, INC. — 49 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-12-06. Screen YMTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for YMTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — YUMANITY THERAPEUTICS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-12-06 | 4 | Peters Richard — President and CEO, Director | Sale (S): 10,890 @ $1.69 | EDGAR |
| 2022-12-06 | 4 | Wyzga Michael D — See Remarks | Sale (S): 3,116 @ $1.69 | EDGAR |
| 2022-12-06 | 4 | Epstein Marie — Principal Accounting Officer | Sale (S): 1,976 @ $1.69 | EDGAR |
| 2022-12-06 | 4 | Smith Devin Whittemore — SVP and General Counsel | Sale (S): 3,116 @ $1.69 | EDGAR |
| 2022-07-06 | 4 | Peters Richard — President and CEO, Director | Sale (S): 4,584 @ $1.85 | EDGAR |
| 2022-06-06 | 4 | Epstein Marie — Principal Accounting Officer | Sale (S): 1,806 @ $1.19 | EDGAR |
| 2022-06-06 | 4 | Smith Devin Whittemore — SVP and General Counsel | Sale (S): 2,923 @ $1.19 | EDGAR |
| 2022-06-06 | 4 | Wyzga Michael D — See Remarks | Sale (S): 2,887 @ $1.19 | EDGAR |
| 2022-06-06 | 4 | Peters Richard — President and CEO, Director | Sale (S): 10,206 @ $1.19 | EDGAR |
| 2022-03-30 | 4 | Peters Richard — President and CEO, Director | Sale (S): 10,715 @ $1.85 | EDGAR |
| 2022-02-07 | 4 | Mohsen Paulash — Chief Business Officer | Sale (S): 1,958 @ $1.83 | EDGAR |
| 2021-12-03 | 4 | Verma Ajay — EVP, Head of R&D | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2021-12-03 | 4 | Epstein Marie — Principal Accounting Officer | Grant/award (A): 12,665 @ $0 | EDGAR |
| 2021-12-03 | 4 | Wyzga Michael D — See Remarks | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2021-12-03 | 4 | Mohsen Paulash — Chief Business Officer | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2021-12-03 | 4 | Smith Devin Whittemore — SVP and General Counsel | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2021-12-03 | 4 | Peters Richard — President and CEO, Director | Grant/award (A): 70,000 @ $0 | EDGAR |
| 2021-11-15 | 4 | Verma Ajay — EVP, Head of R&D | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2021-08-17 | 4 | Wyzga Michael D — See Remarks | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2021-07-07 | 4 | Peters Richard — President and CEO, Director | Tax withholding (F): 4,441 @ $11.11 · Tax withholding (F): 79 @ $10.79 | EDGAR |
| 2021-06-16 | 4 | Smith Devin Whittemore — SVP and General Counsel | Grant/award (A): 58,400 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Kelly Jeffery W. — Director | Grant/award (A): 14,800 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Heyman Richard A. — Director | Grant/award (A): 14,800 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Zydowsky Lynne — Director | Grant/award (A): 14,800 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Allen Patricia L — Director | Grant/award (A): 14,800 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Drapkin Kimberlee C — Director | Grant/award (A): 14,800 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Arkowitz David — Director | Grant/award (A): 14,800 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | PICKETT CECIL B — Director | Grant/award (A): 14,800 (derivative) @ $0 | EDGAR |
| 2021-04-15 | 4 | Verma Ajay — EVP, Head of R&D | Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2021-04-02 | 4 | COLES N ANTHONY — Executive Chair, Director | Grant/award (A): 78,650 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Mohsen Paulash — Chief Business Officer | Grant/award (A): 4,665 @ $0 · Grant/award (A): 37,596 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Peters Richard — President & CEO, Director | Grant/award (A): 60,943 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 · Grant/award (A): 60,944 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Epstein Marie — Principal Accounting Officer | Grant/award (A): 13,329 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Robertson Brigitte — Chief Medical Officer | Grant/award (A): 25,064 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Kelly Jeffery W. — Director | Grant/award (A): 1,959 @ $0 | EDGAR |
| 2021-02-03 | 4 | Heyman Richard A. — Director | Grant/award (A): 1,959 @ $0 | EDGAR |
| 2021-02-03 | 4 | PICKETT CECIL B — Director | Grant/award (A): 1,959 @ $0 | EDGAR |
| 2021-02-03 | 4 | COLES N ANTHONY — Executive Chair, Director | Grant/award (A): 1,118 @ $0 | EDGAR |
| 2020-12-28 | 4 | Epstein Marie — Principal Accounting Officer | Grant/award (A): 38,373 (derivative) · Grant/award (A): 4,216 (derivative) | EDGAR |
| 2020-12-28 | 4 | Peters Richard — President and CEO, Director | Grant/award (A): 235,237 (derivative) | EDGAR |
| 2020-12-28 | 4 | Robertson Brigitte — Chief Medical Officer | Grant/award (A): 59,035 (derivative) | EDGAR |
| 2020-12-28 | 4 | Mohsen Paulash — Chief Business Officer | Grant/award (A): 36,428 · Grant/award (A): 42,168 (derivative) · Grant/award (A): 10,542 (derivative) | EDGAR |
| 2020-12-28 | 4 | Kelly Jeffery W. — Director | Grant/award (A): 6,158 · Grant/award (A): 5,271 (derivative) | EDGAR |
| 2020-12-28 | 4 | Zydowsky Lynne — Director | Grant/award (A): 12,495 (derivative) · Grant/award (A): 5,271 (derivative) | EDGAR |
| 2020-12-28 | 4 | Heyman Richard A. — Director | Grant/award (A): 6,158 · Grant/award (A): 5,271 (derivative) | EDGAR |
| 2020-12-28 | 4 | Allen Patricia L — Director | Grant/award (A): 12,495 (derivative) · Grant/award (A): 5,271 (derivative) | EDGAR |
| 2020-12-28 | 4 | Arkowitz David — Director | Grant/award (A): 4,347 @ $23 | EDGAR |
| 2020-12-28 | 4 | PICKETT CECIL B — Director | Grant/award (A): 6,158 · Grant/award (A): 5,271 (derivative) | EDGAR |
| 2020-12-28 | 4 | COLES N ANTHONY — Executive Chair, Director | Grant/award (A): 689,890 · Grant/award (A): 52,669 · Grant/award (A): 72,496 (derivative) · Grant/award (A): 12,082 (derivative) · Grant/award (A): 6,038 (derivative) | EDGAR |
Recent 8-K events — YUMANITY THERAPEUTICS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-07-01 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-28 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-07 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-10 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-12-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-25 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=YMTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs